These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 30240473)
1. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials. Picchio M; Elisei W; Tursi A J Gastrointestin Liver Dis; 2018 Sep; 27(3):291-297. PubMed ID: 30240473 [TBL] [Abstract][Full Text] [Related]
2. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials. Picchio M; Elisei W; Brandimarte G; Di Mario F; Malfertheiner P; Scarpignato C; Tursi A J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S64-9. PubMed ID: 27622370 [TBL] [Abstract][Full Text] [Related]
3. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials. Iannone A; Ruospo M; Wong G; Barone M; Principi M; Di Leo A; Strippoli GFM Can J Gastroenterol Hepatol; 2018; 2018():5437135. PubMed ID: 30320044 [TBL] [Abstract][Full Text] [Related]
4. Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. Khan RMA; Ali B; Hajibandeh S; Hajibandeh S Colorectal Dis; 2018 Jun; 20(6):469-478. PubMed ID: 29520987 [TBL] [Abstract][Full Text] [Related]
5. Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study. Tursi A; Di Mario F; Brandimarte G; Elisei W; Picchio M; Loperfido S; Dal Bo' N; Ferrara F; Marcello R; Heras Salvat H; Scarpignato C Eur Rev Med Pharmacol Sci; 2013 Dec; 17(23):3244-8. PubMed ID: 24338468 [TBL] [Abstract][Full Text] [Related]
7. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Comparato G; Fanigliulo L; Cavallaro LG; Aragona G; Cavestro GM; Iori V; Maino M; Mazzocchi G; Muzzetto P; Colla G; Sianesi M; Franzé A; Mario FD Dig Dis Sci; 2007 Nov; 52(11):2934-41. PubMed ID: 17410435 [TBL] [Abstract][Full Text] [Related]
8. Mesalazine in preventing acute diverticulitis occurrence: a meta-analysis of randomized controlled trials. Tursi A; Picchio M J Gastrointestin Liver Dis; 2016 Sep; 25(3):409-11. PubMed ID: 27689212 [No Abstract] [Full Text] [Related]
9. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Gatta L; Di Mario F; Curlo M; Vaira D; Pilotto A; Lucarini P; Lera M; Enkleda K; Franzé A; Scarpignato C Intern Emerg Med; 2012 Apr; 7(2):133-7. PubMed ID: 21279478 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Diverticular Disease With Aminosalicylates: The Evidence. Barbara G; Cremon C; Barbaro MR; Bellacosa L; Stanghellini V J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S60-3. PubMed ID: 27622369 [TBL] [Abstract][Full Text] [Related]
11. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. Maconi G; Barbara G; Bosetti C; Cuomo R; Annibale B Dis Colon Rectum; 2011 Oct; 54(10):1326-38. PubMed ID: 21904150 [TBL] [Abstract][Full Text] [Related]
12. Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease. Festi D; Colecchia A Am J Gastroenterol; 2009 Feb; 104(2):532. PubMed ID: 19174809 [No Abstract] [Full Text] [Related]
13. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Tursi A; Brandimarte G; Daffinà R Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485 [TBL] [Abstract][Full Text] [Related]
14. Rationale and evidences for treatment of symptomatic uncomplicated diverticular disease. Cuomo R; Cargiolli M; Andreozzi P; Zito FP; Sarnelli G Minerva Gastroenterol Dietol; 2017 Jun; 63(2):130-142. PubMed ID: 27973463 [TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study. Kruis W; Meier E; Schumacher M; Mickisch O; Greinwald R; Mueller R; Aliment Pharmacol Ther; 2013 Apr; 37(7):680-90. PubMed ID: 23414061 [TBL] [Abstract][Full Text] [Related]
16. Mesalamine (5-ASA) for the prevention of recurrent diverticulitis. Carter F; Alsayb M; Marshall JK; Yuan Y Cochrane Database Syst Rev; 2017 Oct; 10(10):CD009839. PubMed ID: 28973845 [TBL] [Abstract][Full Text] [Related]
18. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. Tursi A; Brandimarte G; Giorgetti GM; Elisei W J Clin Gastroenterol; 2006 Apr; 40(4):312-6. PubMed ID: 16633103 [TBL] [Abstract][Full Text] [Related]
19. New medical strategies for the management of acute diverticulitis. Tursi A Expert Rev Gastroenterol Hepatol; 2015; 9(10):1293-304. PubMed ID: 26289102 [TBL] [Abstract][Full Text] [Related]
20. Use of mesalazine in diverticular disease. Di Mario F; Comparato G; Fanigliulo L; Aragona G; Cavallaro LG; Cavestro GM; Franzé A J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S155-9. PubMed ID: 16885700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]